A5027756423- PI3K/AKT/mTOR signaling in cancer
- RNA and protein synthesis mechanisms
- CRISPR and Genetic Engineering
- Cancer-related gene regulation
- Protein Degradation and Inhibitors
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Epigenetics and DNA Methylation
- Chemical Synthesis and Analysis
- Click Chemistry and Applications
University of Michigan
2023-2025
Eukaryotic translation initiation factor 4E (eIF4E) is an RNA-binding protein that binds to the m7GpppX-cap at 5′ terminus of coding mRNAs initiate cap-dependent translation. While all cells require translation, cancer become addicted enhanced translational capacity, driving production oncogenic proteins involved in proliferation, evasion apoptosis, metastasis, and angiogenesis, among other cancerous phenotypes. eIF4E rate-limiting factor, its activation has been shown drive initiation,...
Dysregulation of translation is a hallmark cancer that enables rapid changes in cellular protein production to shape oncogenic phenotypes. Translation initiation governed by the m7GpppX cap-binding eukaryotic factor 4E (eIF4E), rate-limiting cap-dependent initiation. eIF4E overexpressed many cancers and drives oncoproteins promote tumor growth survival. Accordingly, has been established as an attractive albeit challenging therapeutic target. Building upon our previous work developing...
Eukaryotic translation initiation factor 4E (eIF4E) is an RNA-binding protein that binds to the m
Melanoma is the deadliest form of skin cancer with a 5-year survival rate less than 20%. While significant strides have been made in field kinase-targeted and immune-based therapies for melanoma, development resistance to these therapeutic agents has hindered success treatment. Drug-resistant melanoma particularly reliant on enhanced cap-dependent translation drive production oncoproteins that promote growth survival. The m